Positive Data Shows Promise of 5-MeO-DMT in Patients When Used With SSRIs
Last reviewed and updated: June 24, 2026.
Key Takeaways
| SSRI + efficacy | 5-MeO-DMT retains efficacy in SSRI users — unlike psilocybin/LSD (blunted by 5-HT2A downregulation); 5-MeO-DMT’s 5-HT1A/sigma-1 profile appears less affected |
| Safety caveat | Serotonin syndrome risk is real when combining serotonergic substances with SSRIs — research done in supervised clinical settings; do not self-administer without medical guidance |
| vs DMT | Non-visual (ego dissolution/unity) vs DMT’s visual/entity experiences; shorter duration (15–45 min); more psychologically intense for many users |
| Clinical pipeline | TRD, anxiety, PTSD, addiction; short duration = practical for supervised sessions; several biotechs developing synthetic formulations |
| Legal status | Schedule I U.S.; Mexico legal (retreat programs); Colorado Prop 122 includes DMT for personal possession; not covered by Oregon Measure 109 |
Beckley Psytech has released encouraging results from its Phase 2a clinical trial of BPL-003, a synthetic formulation of 5-MeO-DMT. The psychedelic compound was administered to patients with treatment-resistant depression (TRD) who remained on a stable dose of selective serotonin reuptake inhibitors (SSRIs).
New: Interested in Being Part of a Psychedelics-Focused Clinical Trial? Sign Up Here
Historically, most psychedelic studies have excluded patients taking SSRIs due to safety concerns and fears of reduced efficacy. This trial marks a significant departure, with results that may reshape how clinicians think about combining traditional antidepressants and psychedelic therapy.
Key Takeaways from the Study
| Category | Details |
|---|---|
| Compound | BPL-003 (intranasal 5-MeO-DMT) |
| Patient Population | Individuals with treatment-resistant depression on SSRIs |
| Safety Profile | No serious adverse events reported |
| Onset of Psychedelic Effects | ~15 minutes after dosing |
| Duration of Psychedelic Experience | Approximately 30 minutes |
| Efficacy Signal | Rapid and robust reduction in depressive symptoms |
| Trial Phase | Phase 2a |
| Dosing Protocol | Single dose of BPL-003 + psychotherapy |
Looking for treatment? Find ketamine clinics closest to you as well as other psychedelic therapies in your area.
Fast Acting, Short Duration
One of the most striking features of BPL-003 is its pharmacokinetics. The psychedelic experience typically begins within 15 minutes and resolves within 30 minutes. This shorter time window may improve the practicality and scalability of psychedelic therapy in clinical settings, compared with compounds like psilocybin which can last several hours.
Despite the brief duration, the results were notable. Patients experienced a rapid and sustained reduction in depression scores, suggesting that even a short psychedelic experience can produce meaningful therapeutic outcomes when supported by structured therapy.
Safety and Co-Administration with SSRIs
A major concern in the field has been whether SSRIs would blunt the effects of psychedelics or increase the risk of adverse reactions. This study found no such interactions. There were no serious side effects, and patients tolerated the combination well. This outcome challenges the prevailing approach of requiring SSRI washout periods prior to psychedelic treatment.
Implications for Future Research
These results could have wide-ranging implications. By expanding the pool of eligible patients to include those who are already on SSRIs, psychedelic research and therapy may become more accessible. Beckley Psytech plans to continue development of BPL-003 with additional trials focused on efficacy, dosing, and long-term outcomes.
The findings offer new momentum for integrating psychedelic therapies into mainstream psychiatric care, especially for those who have exhausted conventional options.
5-MeO-DMT With SSRIs: What the Research Shows and Why It Matters
One of the most clinically important questions in psychedelic-assisted therapy is what happens when patients who take SSRIs (the most commonly prescribed antidepressants) participate in psychedelic sessions. The answer has historically been a barrier — and new data on 5-MeO-DMT is beginning to clarify it.
The SSRI problem in psychedelic research. SSRIs reduce 5-HT2A receptor sensitivity over time through receptor downregulation. Since classical psychedelics (psilocybin, LSD) act primarily at 5-HT2A receptors, SSRI users have historically been excluded from psychedelic clinical trials — both due to theoretical interaction risks and because SSRIs were expected to blunt psychedelic effects (the “SSRI blunting” phenomenon). This is a significant clinical problem: SSRIs are taken by an estimated 13% of Americans, and the very patients most likely to seek psychedelic therapy for depression are also most likely to be on SSRIs. If psychedelics only work for SSRI-naive patients, access is severely limited for the population that most needs alternative treatments.
Why 5-MeO-DMT is different from psilocybin in this context. 5-MeO-DMT has a different receptor profile than psilocybin or LSD. While it does act at serotonin receptors (including 5-HT2A), it also has significant sigma-1 receptor activity and different binding kinetics. Crucially, 5-MeO-DMT’s primary subjective effects appear to involve 5-HT1A receptor activation (producing the characteristic non-visual, profound unity/dissolution experience) as much as 5-HT2A. This different mechanism may mean that SSRIs — which downregulate 5-HT2A specifically — blunt it less than they blunt classical psychedelics. The study data showing 5-MeO-DMT efficacy in SSRI users is significant because it suggests this compound may provide a viable therapeutic option for a population currently excluded from most psychedelic research.
Serotonin syndrome risk: the essential safety caveat. While the efficacy data is encouraging, combining any serotonergic compound with SSRIs requires careful attention to serotonin syndrome risk. Serotonin syndrome results from excessive serotonergic activity and can range from mild (tremor, diarrhea) to severe (hyperthermia, seizures, death). 5-MeO-DMT is highly serotonergic. The studies reporting positive outcomes in SSRI users did so in supervised clinical settings with appropriate screening and monitoring — not uncontrolled self-administration. Any SSRI user considering psychedelic use outside a supervised clinical setting should be aware that serotonin syndrome risk is real and not trivial, particularly with MAO inhibitor combinations (which are absolutely contraindicated).
Frequently Asked Questions
Can you take 5-MeO-DMT if you’re on SSRIs?
Emerging research suggests 5-MeO-DMT may retain efficacy in SSRI users — which is clinically significant because SSRIs typically blunt the effects of classical psychedelics (psilocybin, LSD) through 5-HT2A receptor downregulation. 5-MeO-DMT’s different receptor profile (significant 5-HT1A and sigma-1 activity) appears to make it less susceptible to SSRI blunting. However, combining any serotonergic substance with SSRIs carries serotonin syndrome risk — which ranges from mild to life-threatening. This is not a recommendation to self-administer 5-MeO-DMT while on SSRIs outside a medical setting. The research was conducted in supervised clinical environments with appropriate screening. Consult your prescribing physician before combining SSRIs with any serotonergic substance.
What is 5-MeO-DMT and how is it different from DMT?
5-MeO-DMT (5-methoxy-N,N-dimethyltryptamine) and DMT (N,N-dimethyltryptamine) are related tryptamine compounds but produce distinctly different experiences. DMT produces intense, highly visual experiences with complex geometric patterns and often “entities” or alternative realities — typically 15–30 minutes when smoked. 5-MeO-DMT produces a non-visual experience of overwhelming intensity: ego dissolution, a sense of unity or void, profound psychological impact — typically 15–45 minutes when inhaled. Many users describe 5-MeO-DMT as more psychologically demanding than DMT. Pharmacologically, 5-MeO-DMT has stronger 5-HT1A and sigma-1 receptor activity relative to DMT, which partly explains the different character of effects. Both are Schedule I in the U.S. 5-MeO-DMT occurs naturally in Bufo alvarius toad venom (Colorado River toad) and in various plants.
What conditions is 5-MeO-DMT being studied for?
5-MeO-DMT is being studied primarily for: (1) Treatment-resistant depression — multiple studies show rapid antidepressant effects, often after a single session; (2) Anxiety and existential distress — particularly in cancer patients or end-of-life contexts; (3) PTSD — early data from retreat settings in Mexico (where 5-MeO-DMT is legal) and clinical trials; (4) Addiction — some evidence from treatment programs. The compound has attracted clinical interest partly because of its short duration (15–45 min vs 4–6 hours for psilocybin), which could make supervised clinical sessions more practical. Several biotech companies are developing synthetic 5-MeO-DMT formulations for clinical use. Most current research is early-stage (Phase 1/2) with the exception of some larger observational studies from retreat settings.
Is 5-MeO-DMT legal?
5-MeO-DMT is Schedule I in the United States — federally illegal with no approved medical use. It is not covered by Oregon’s Measure 109 (which covers psilocybin only) or Colorado’s Proposition 122 initially (though Colorado’s law includes a pathway to add other natural psychedelics through regulatory review — DMT and mescaline were included in the initial legalization alongside psilocybin). Mexico does not specifically control 5-MeO-DMT, which is why retreat programs in Mexico operate legally using it. Church-based programs in the U.S. have attempted to use First Amendment religious freedom arguments to protect 5-MeO-DMT use, with limited legal success. The regulatory trajectory for 5-MeO-DMT lags behind psilocybin given the smaller clinical evidence base.
